Chamber and committees

The Scottish Government's international offices are updated on all areas outlined in the Programme for Government including the constitution.

Key recommendations in the Heart Valve Voice report State of the Nation included:

1) collecting standardised data for HVD.

2) focus on HVD in campaigns to raise awareness of disease in women.

3) developing an optimal patient pathway for HVD.

4) improving access to echocardiography.

1) The Heart Disease Action Plan (2021) clearly sets out our priority for the effective use of high-quality, standardised data to support clinical decision-making, understand patient outcomes and enable better service-planning. In April 2021, we commissioned Public Health Scotland to develop the Scottish Cardiac Audit Programme. We have committed more than £1.5m over five years to support this transformative change in access to, and use of, data to drive improvement in cardiac services.

2) We have made clear commitments to tackling the inequalities faced by women with heart disease in our Women’s Health Plan, including the launch of an information campaign on women’s heart health. Future development of work in this area will be informed by the lived experience of women with heart disease.

3) Priority 2 within the Heart Disease Action Plan makes clear our commitment to developing nationally agreed pathways of care for all cardiac conditions. This work is underway.

4) We recognise the importance of improving access to echocardiography and are taking action to address this. Through the Heart Disease Action Plan funding call in 2021, we provided funding for a project exploring how to improve access to echocardiography.

The Scottish Government recognises that COVID-19 is an unprecedented global crisis, leaving no part of the world unaffected. Although Scotland is not a member of the COVAX scheme, we will continue engaging with the UK Government on that matter. On 8 December, the First Minister wrote to the Prime Minister to urge the UK government to end its opposition at the World Trade Organisation and to join over 100 countries who are now supportive of a temporary Trade-related Aspects of Intellectual Property Rights waiver.

We have also provided international development support to our partner countries to support their COVID-19 responses, including vaccine preparedness.

In December 2020 we provided international development funding to support vaccine preparedness and delivery, including £2M to UNICEF in 2020 to help vaccine distribution, roll-out and online healthcare education in our partner countries.

In September 2021, we provided £250,000 from our international development fund to leverage the provision to our partner countries of £11.2 million worth of PPE – our single biggest ever donation – to aid COVID responses as part of our strategic response.

In February 2022 we provided £1.5m to UNICEF to support equal access to COVID-19 vaccines in our partner countries. The funds will support vaccination programmes in Rwanda, Zambia and Malawi, their provision of safe oxygen supplies, and help the agency deliver equipment, resources and technical support in response to the pandemic.

Where it is clinically appropriate to do so, patients of all ages will be examined with a stethoscope to listen for breathing and heart sounds. They may also have ECG electrical recordings of their heart rate, blood tests and have access to other investigations such as echocardiograms, rhythm monitors and blood pressure recordings, should these be required.

The Heart Disease Action Plan (2021) outlines our commitment to exploring innovative models of care for the diagnosis of heart disease, including a focus on improving access to echocardiography in the most appropriate setting for local needs.

The Scottish Government is committed to ensuring that all school-aged children and young people in Scotland have access to a digital device by the end of this parliament in 2026.

The contract with KPMG to construct the business case for the National Care Service has not been suspended.

Current guidance is being reviewed in collaboration with the sector, taking into account advice provided by the Covid-19 Advisory Sub-Group on Colleges and Universities. The Scottish Government’s 4 Harms approach ensures that the fullest range of impacts is taken into account in developing measures or guidance in all sectors, including for universities and colleges. Some students will already be receiving full time in-person teaching in line with our advice to prioritise students whose qualifications/progression are at risk. It is also for institutions to determine an appropriate balance between online and in-person teaching where that focuses on the reduction and management of risk and a cautious approach to keep people safe.

Kaftrio ® has been available for the treatment of cystic fibrosis in patients aged 12 years and older since 1 September 2020. This follows a pricing agreement with the manufacturer. There is provision in the access policy and pricing agreement for expanding access to Kaftrio ® as licence extensions are granted by the Medicines and Healthcare products Regulatory Agency (MHRA). The most recent extension in January 2022 allows for Kaftrio ® to be used in children aged 6 to 11 years.

This means that clinicians - working in cystic fibrosis treatment centres - can now prescribe Kaftrio ® for younger patients whom they consider will benefit from its use.

I refer the member to the answer to question S6W-06258 on 15 February 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

I refer the member to the answer to question S6W-06258 on 15 February 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers